Akkawi Ibrahim, Zmerly Hassan
Orthopaedics and Traumatology Unit, Villa Erbosa Hospital, Bologna, Italy.
Joints. 2018 Jun 14;6(2):122-127. doi: 10.1055/s-0038-1660790. eCollection 2018 Jun.
Osteoporosis is a worldwide disease characterized by reduction of bone mass and alteration of bone architecture resulting in increased bone fragility and increased fracture risk. Causes of osteoporosis include increasing age, female sex, postmenopausal status, hypogonadism or premature ovarian failure, low body mass index, ethnic background, rheumatoid arthritis, low bone mineral density (BMD), vitamin D deficiency, low calcium intake, hyperkyphosis, current smoking, alcohol abuse, immobilization, and long-term use of certain medications. The diagnosis of osteoporosis is established by measurement of BMD of the hip and spine using dual energy X-ray absorptiometry. According to the World Health Organization criteria, osteoporosis is defined as a BMD that lies 2.5 standard deviation or more below the average value for young healthy women. Bone turnover biomarker detection may be useful in monitoring osteoporosis treatment and assessing fracture risk but not for diagnosis of osteoporosis. Management of osteoporosis consists of nonpharmacological interventions, which are recommended for all subjects, and pharmacological therapy in all postmenopausal women who have had an osteoporotic fracture or have BMD values consistent with osteoporosis.
骨质疏松症是一种全球性疾病,其特征是骨量减少和骨结构改变,导致骨脆性增加和骨折风险升高。骨质疏松症的病因包括年龄增长、女性性别、绝经后状态、性腺功能减退或卵巢早衰、低体重指数、种族背景、类风湿性关节炎、低骨矿物质密度(BMD)、维生素D缺乏、钙摄入不足、脊柱后凸、当前吸烟、酗酒、制动以及长期使用某些药物。骨质疏松症的诊断通过使用双能X线吸收法测量髋部和脊柱的BMD来确定。根据世界卫生组织的标准,骨质疏松症被定义为BMD比年轻健康女性的平均值低2.5个标准差或更多。骨转换生物标志物检测在监测骨质疏松症治疗和评估骨折风险方面可能有用,但不能用于骨质疏松症的诊断。骨质疏松症的管理包括非药物干预措施(推荐给所有患者)以及对所有发生过骨质疏松性骨折或BMD值符合骨质疏松症的绝经后女性进行药物治疗。